Editor in Chief Dr KK Aggarwal, Padma Shri Awardee                                                                               Dated:04 August,2020

Next big covid-19 treatment may be manufactured antibodies

As the world awaits a covid-19 vaccine, the next big advance in battling the pandemic could come from a class of biotech therapies widely used against cancer and other disorders - antibodies designed specifically to attack this new virus. ,Development of monoclonal antibodies to target the virus has been endorsed by leading scientists. Anthony Fauci, the top U.S. infectious diseases expert, called them "almost a sure bet" against covid-19. ,When a virus gets past the body's initial defenses, a more specific response kicks in, triggering production of cells that target the invader. These include antibodies that recognize and lock onto a virus, preventing the infection from spreading. ....read more

Public perceptions about COVID-19

Join us today as we talk about beliefs and attitudes of the public about the COVID-19 pandemic at 7:00 PM on MEDtalks with Dr K K Aggarwal.
Just click on www.facebook.com/drkkaggarwal or https://perfecthealthmela.com/vevent/general-webinar.php

CMAAO Coronavirus Facts And Myth Buster: COVID-19 Update

With inputs from Dr Monica Vasudev
1035: An analysis of primary human lung cells that were infected in the lab with SARS-CoV-2 revealed how the cells accumulated large amounts of lipid droplets. Following infection, the lung proteins downregulate the ability of lung cells to burn carbohydrates and fatty acids. Lung cells cannot hold fat. This could possibly explain some of the severe damage that is done to the lungs of patients with COVID-19. The virus depends on glucose uptake, cholesterol production, and fatty acid oxidation. Additional research is needed on the cholesterol drug fenofibrate before clinical trials can start. ....read more

World COVID Meter 3rd August: India Number 3, 213 Countries Affected

Cases: 1M April 2, 2M April 15, 3M April 27, 4M May 8, 5M May 20, 6M May 30, 7M June 7, 8M June 15, 9M June 22, 10M June 29th, 11M July 4, 12M July 8, 13M July 13, 14M July 17, 15M July 23, 16M July 25, 17M July 29, 18M August 1 ,Ground Zero: Wuhan - in live animal market or cafeteria for animal pathogens: 10th January; Total cases are based on RT PCR, 67% sensitivity ,Coronavirus Cases: 18,231,535,Deaths: 692,694,Recovered: 11,443,844 ,ACTIVE CASES: 6,094,997,Currently Infected Patients 6,029,244 (99%) in Mild Condition....read more

Wahans (Vehicles) In Mythology

In mythological world, the negative tendency of an individual is symbolized with animal nature. Gods in Indian mythology have been symbolized as living a positive behavior. Every God has a vehicle or Wahan. Both God and the Wahan symbolize how to live a positive life and how to control the animal tendencies.
A few examples:Lord Ganesha’s vehicle is a Mouse. Mouse in mythology symbolizes greed and Ganesha is the one who removes obstacles. The spiritual meaning behind the two is “one should learn to control greed to tackle obstacles in life”. ,Lord Shiva rides Nandi, the Bull. Bull symbolizes uncontrolled sexual desires. The duo signifies that to learn meditation, one needs to control sexual desires first. ....read more

Video of The day

Do not ignore day 5 after the first symptom in COVID 19



Healthcare News Monitor
With RIL eyeing Netmeds deal, online pharma set for consolidation
ET Tech

India’s online pharmacy space is expected to see a wave of consolidation, triggered by Reliance Industries’ reported acquisition of Chennai-based Netmeds, with global investors also lining up to back the winners in the fast-growing sector. Reliance’s yet-to-be announced acquisition of Netmeds for an estimated $120 million is a catalyst for other players such as PharmEasy and Medlife to explore merger and acquisition negotiations, multiple sources told ET. The Mumbai-based PharmEasy – backed by Temasek, CDPQ and Orios Venture Partners –could acquire its Bengaluru-based rival in a primarily stock deal valued at $120-$150 million, the sources said. Multiple global financial investors, including US private equity firm TPG which has a strong healthcare focused portfolio, could also invest in the combined entity if the merger goes through.

Jubilant Life Sciences launches JUBI-R for COVID-19 treatment

Jubilant Life Sciences’ subsidiary, Jubilant Generics has launched remdesivir for injection under the brand name ‘JUBI-R’ in the Indian market at a price of Rs 4,700 per vial of 100 mg (lyophilized injection). ,The company will make the drug available to over 1,000 hospitals providing COVID-19 treatment in India through its distribution network. ,A company statement informed, “Jubilant’s 24-hour helpline will enhance access to ‘JUBI-R’ during these pandemic times, where timely access to the drug may prove critical to treatment outcomes. In order to increase the accessibility of ‘JUBI-R’ to patients below the poverty line and to front line paramedical staff, Jubilant Bhartia Foundation, a not-for-profit organisation of Jubilant Group, is launching unique programs in India aimed at the distribution of the drug.”

Karnataka doctor cheers up coronavirus patients with his birthday bash
India TV

A 28-year-old doctor from Karnataka's Ballari district has celebrated his birthday with coronavirus patients to cheer them up as most of them are gloomy in isolation, said an official on Monday. ,"With an intention to spread positive vibes among Covid patients, Dr Sohail Saifuddin Inamdar celebrated his birthday at O P Jindal Centre, a dedicated Covid care facility, by distributing cake and biscuits," said Ballari deputy commissioner S.S. Nakul to IANS. ,The special birthday bash occurred at Torangallu in Ballari district's Sandur Taluk, 316 km north of Bengaluru, where the Jindal steel plant and township is located. ,Inamdar, an orthopaedics medical student, had just completed his final year post-graduate course examination at Vijayangara Institute of Medical Sciences (VIMS) in Ballari.

Mumbai: Doctor pursuing diploma seeks HC intervention for degree certificate

Mumbai: The Bombay high court (HC) has directed a petitioner doctor to amend his plea and add a request to be included in a 2018 notification issued by Maharashtra government that had changed the status of two-year diploma courses for post-graduate (PG) medical students to a three-year degree course. ,All diploma courses were changed to three-year degree courses in June 2018, a month after the petitioner took the admission for it. ,Though the petitioner completed the two-year diploma course in March, he has been asked to persist with it because of the ongoing coronavirus disease (Covid-19) outbreak. ,He submitted before the court that he should get a P-G degree because he has to continue the course for another nine months.